Ben Tre Pharmaceutical Joint Stock Company

HOSE:DBT Stock Report

Market Cap: ₫250.5b

Ben Tre Pharmaceutical Past Earnings Performance

Past criteria checks 0/6

There is insufficient data on Ben Tre Pharmaceutical's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals Industry Growth13.0%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Jun 2020

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Ben Tre Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

HOSE:DBT Revenue, expenses and earnings (VND Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 20828,64016,892170,1730
31 Mar 20825,16120,644166,6380
31 Dec 19800,50021,396155,6290
30 Sep 19786,07322,218158,2380
30 Jun 19813,11621,993155,9830
31 Mar 19806,11821,904150,8430
31 Dec 18809,91420,193153,7710
30 Sep 18789,99325,707148,3600
30 Jun 18759,04628,075154,2740
31 Mar 18795,64227,416157,8660
31 Dec 17800,11428,737154,7830
30 Sep 17752,71320,745141,7730
30 Jun 17715,36119,438123,0430
31 Mar 17638,42422,475114,7990
31 Dec 16580,51723,662107,8150
30 Sep 16567,72328,232125,4510
30 Jun 16558,42025,129128,0070
31 Mar 16555,70625,195122,4790
31 Dec 15552,11622,203122,7300
30 Sep 15536,75713,497120,7180
30 Jun 15529,24515,075117,2240
31 Mar 15524,66312,236113,9150
31 Dec 14523,25511,368107,4290
30 Sep 14474,23511,19192,8780
30 Jun 14485,21510,74694,2440
31 Mar 14512,79111,22399,4480

Quality Earnings: DBT has a high level of non-cash earnings.

Growing Profit Margin: Insufficient data to determine if DBT's profit margins have improved over the past year.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if DBT's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare DBT's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if DBT's earnings growth over the past year exceeded the Pharmaceuticals industry average.

Return on Equity

High ROE: DBT has a negative Return on Equity (0%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 03:19
End of Day Share Price 2025/01/02 00:00
Earnings2020/06/30
Annual Earnings2019/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ben Tre Pharmaceutical Joint Stock Company is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution